Published in Curr Opin Immunol on February 27, 2015
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest (2015) 1.41
Targeting human melanoma neoantigens by T cell receptor gene therapy. J Clin Invest (2016) 0.92
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. Mol Ther (2016) 0.80
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. Trends Pharmacol Sci (2015) 0.79
Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers. Leukemia (2016) 0.78
MHC class I-associated peptides derive from selective regions of the human genome. J Clin Invest (2016) 0.77
A folate receptor-targeted lipoplex delivering interleukin-15 gene for colon cancer immunotherapy. Oncotarget (2016) 0.77
New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies. Clin Cancer Res (2015) 0.76
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. J Immunol Res (2016) 0.76
Receptor combinations hone T-cell therapy. Nat Biotechnol (2016) 0.76
Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS). Sci Rep (2016) 0.75
The T210M Substitution in the HLA-a*02:01 gp100 Epitope Strongly Affects Overall Proteasomal Cleavage Site Usage and Antigen Processing. J Biol Chem (2015) 0.75
Recent advances in T-cell engineering for use in immunotherapy. F1000Res (2016) 0.75
New approaches for the immunotherapy of acute myeloid leukemia. Discov Med (2015) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Cancer genome landscapes. Science (2013) 25.33
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 10.10
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Modulation of microRNA processing by p53. Nature (2009) 7.88
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature (2005) 3.70
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature (2014) 3.42
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 2.81
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Bystander elimination of antigen loss variants in established tumors. Nat Med (2004) 2.53
Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst (1974) 2.47
A unique tumor antigen produced by a single amino acid substitution. Immunity (1995) 2.33
Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science (2012) 2.26
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 2.22
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18
A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol (2007) 2.00
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med (1997) 2.00
Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J Immunol (1999) 1.86
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med (2014) 1.80
The cancer antigenome. EMBO J (2012) 1.78
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med (2008) 1.70
CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res (2014) 1.66
Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med (1984) 1.60
Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res (2012) 1.58
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res (2014) 1.56
The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. Blood (2011) 1.56
Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol (2013) 1.50
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
Retroviral insertion mutagenesis in mice as a comparative oncogenomics tool to identify disease genes in human leukemia. Mol Ther (2007) 1.39
HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res (2014) 1.37
Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am (2006) 1.37
Multiple tumour-specific antigens expressed on a single tumour cell. Nature (1983) 1.36
Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol (2013) 1.34
HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J Immunol (2013) 1.32
The determinants of tumour immunogenicity. Nat Rev Cancer (2012) 1.28
Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res (1990) 1.28
The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein. Proc Natl Acad Sci U S A (2001) 1.27
High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res (2001) 1.26
A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology (2012) 1.20
Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens. J Exp Med (2001) 1.20
Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J Immunol (2005) 1.19
Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res (2013) 1.18
Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res (2013) 1.15
A cancer immunosurveillance controversy. Nat Immunol (2004) 1.11
Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J Clin Invest (2013) 1.10
How pure are inbred strains of mice? Immunol Today (1982) 1.05
Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. Oncoimmunology (2013) 1.03
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology (2014) 1.01
Why do we not all die of cancer at an early age? Adv Cancer Res (2007) 0.97
MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis (2012) 0.95
Fas expression by tumor stroma is required for cancer eradication. Proc Natl Acad Sci U S A (2013) 0.95
MHC multimer-guided and cell culture-independent isolation of functional T cell receptors from single cells facilitates TCR identification for immunotherapy. PLoS One (2013) 0.92
In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census. Oncoimmunology (2012) 0.92
Tracking the common ancestry of antigenically distinct cancer variants. Clin Cancer Res (2001) 0.90
Adaptive immunity does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer. J Immunol (2013) 0.89
Immunodominance in the immune response to "multiple" histocompatibility antigens. Immunogenetics (1982) 0.87
T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer. Cancer Immunol Immunother (2012) 0.82
Generation of transgenic mice with megabase-sized human yeast artificial chromosomes by yeast spheroplast-embryonic stem cell fusion. Nat Protoc (2013) 0.81
The forty-year-old mutation theory of Luria and Delbrück and its pertinence to cancer chemotherapy. Adv Cancer Res (1983) 0.80
Contribution of TCR signaling strength to CD8+ T cell peripheral tolerance mechanisms. J Immunol (2014) 0.80
Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes. Clin Cancer Res (2012) 0.79
Genetically engineered vaccines. Comparison of active versus passive immunotherapy against solid tumors. Ann N Y Acad Sci (1993) 0.77